Vectura Group’s Post

Approximately 6.7 million Americans over 20 years old have #heartfailure, which is expected to rise to 8.5 million Americans by 2030. Join us at OM1, Inc. Feb 12-16th for Heart Failure week. Pharma companies are paying anywhere from $75K to $5M per year to acquire datasets that can speed up drug discovery, clinical trial design, and regulatory reporting. Top 10 Pharma uses OM1’s Heart Failure (HF) dataset to drive insights from both observed and amplified endpoints such as LVEF and NYHA. OM1 helps to fill crucial gaps not readily available in RWD through extraction of clinical notes by machine learning and extraction. Including this information in the HF data set can greatly improve assessment of the patient journey and the evaluation of treatment outcomes in the HF patient population and within different clinical phenotypes. The estimation model for NYHA (eNYHA) has been validated and a methodology publication is in progress. Interested in learning more? 📍 https://lnkd.in/edaasdns #HFWeek2024 #heartfailure #HFWeek2024 #hearthealth

Systemic (Intravenous) delivery involves administering in a way that allows it to travel throughout the entire body via the bloodstream. This method is suitable for therapies that need to reach various organs or tissues. In contrast, regional drug delivery targets a specific region or site within the body, often by directly administering the medication to that area and concentrates the drug's effects in a localized manner. The choice between systemic and regional routes depends on the therapeutic goals and the specific characteristics of the drug and the targeted condition. Genelux is dedicated to providing virotherapeutics that enable physician-preferred routes of administration. #Stage4NeedsMore #DrugResearch #Nasdaq #HealthcareInvesting #BiotechInnovation #NSCLC #SCLC #SystemicAdministration #immunotherapy

🔬 Breaking New Ground in Hemophilia A Treatment 💡 Exciting news from Novo Nordisk resonates through the pharma world as their game-changing Mim8 secures a win in Phase 3 trials, potentially shifting the landscape of hemophilia A treatment! 🌐 A direct challenge to Roche's Hemlibra, Mim8 has met its primary endpoints with once-weekly and once-monthly administration. Demonstrated reductions in treated bleeds and a commendable safety profile pave the way for potential regulatory approval by year-end. 🎯 Innovation isn't the only victory here. Convenience could be a game-changer with Mim8's "true monthly profile". Contrast that with Hemlibra's initial weekly doses before varying maintenance schedules. 🔄 With over 70% of patients potentially bleed-free, Novo's vision is clear - improving patient quality of life while simplifying treatment. And yet, amidst this milestone, Roche stands firm on Hemlibra's established efficacy and real-world data backing. 💊 As we await further developments, the focus shifts to patient choice, accessibility, and how Novo Nordisk will navigate the market dynamics against a formidable competitor. Will Mim8 usher in a new era for hemophilia care? Only time will tell. 🕒 #HemophiliaTreatment #PharmaceuticalInnovation #HealthcareProgress

📈 For the first time since 2022, we've been able to add a new therapy to our patient tracker! Amtagvi® was approved by the FDA in February 2024, and has since treated its first 25 patients. While it's a step in the right direction to see another therapy make it to market, the broader picture still shows we’re lagging behind. More patients are being treated than ever before, but challenges including manufacturing and delivery continue to significantly limit access. If we don’t move faster to solve these issues, more and more eligible patients may continue to be unable to access these life-saving therapies. See how many patients have accessed CAR-Ts in 2024, so far ➡️ https://lnkd.in/exdRgSfZ #ManufacturingBrighterFutures #CellTherapy #GeneTherapy #PatientAccess #Biotechnology Disclaimer: These numbers are inferred from publicly reported revenue numbers and are directionally correct but may not be precise. They don't account for patients previously treated in clinical trials or on compassionate use.

Have you seen the latest issue of Med? It's online now: https://hubs.li/Q02HYnC00 On the cover: Chemotherapies are currently dosed based on a patient's height and weight, using an equation from 1916 to estimate their body surface area. This method leads to variability in pharmacokinetics, potentially causing increased toxicities and decreased efficacy. Personalized dosing could improve the patient's experience by providing a more accurate dose, reducing side effects and increasing drug efficacy. In this issue of Med, DeRidder et al. develop a closed-loop automated drug infusion regulator (CLAUDIA) system to address this challenge by ensuring the drug reaches the target concentration regardless of other factors. This illustration depicts a positive treatment experience, with patients walking unbothered by their personalized chemotherapy dose represented by colorful IV bags floating like balloons. Recovery is gentler, and daily life is less impacted by chemotherapy. Cover credit: Virginia E. Fulford.

https://lnkd.in/gpcgbK4E Key Insights: • The FARAPULSE PFA System offers a unique approach, utilizing tissue-selective, non-thermal electric fields for heart tissue ablation, avoiding damage to surrounding structures during the procedure Visit MedicoInsights to explore key insights #HealthcareNews #drugs #StayInformed #MedicalNews #drugapproval #HealthTrends #Insights #HealthIndustry #HealthInnovation #bostonscientific #devices #HealthcareAnalytics #NewsUpdate #HealthcareNetworking #pharma #pharmaceuticals #pharmanews #pharmaindustry #pharmainnovation #update #medicoinsights

Approximately 6.7 million Americans over 20 years old have #heartfailure, which is expected to rise to 8.5 million Americans by 2030. Join us at OM1, Inc. Feb 12-16th for Heart Failure week.  Pharma companies are paying anywhere from $75K to $5M per year to acquire datasets that can speed up drug discovery, clinical trial design, and regulatory reporting. Top 10 Pharma uses OM1’s Heart Failure (HF) dataset to drive insights from both observed and amplified endpoints such as LVEF and NYHA. OM1 helps to fill crucial gaps not readily available in RWD through extraction of clinical notes by machine learning and extraction. Including this information in the HF data set can greatly improve assessment of the patient journey and the evaluation of treatment outcomes in the HF patient population and within different clinical phenotypes. The estimation model for NYHA (eNYHA) has been validated and a methodology publication is in progress. Interested in learning more? 📍 https://lnkd.in/edaasdns #clinicaltrials #heartfailure #HFWeek2024 #hf

✨Join Dr. Katharina Schwarz for a Webinar ✨ We’re thrilled to partner with SCIREQ Scientific Respiratory Equipment Inc. and The 3Rs Collaborative (3RsC) to bring you an insightful session led by Katharina Schwarz from Fraunhofer ITEM. Dive into cutting-edge strategies that are revolutionizing drug development for inhalable therapeutics through predictive #invitro and #exvivo models: 📅October 29th, 10-11am, via Zoom! 💡🔎 What you’ll discover: ▶️Precision-Cut Lung Slices (PCLS): Assess drug efficacy and respiratory toxicity of inhalable treatments ▶️P.R.I.T.® ExpoCube® System: Experience dose-controlled, air-liquid-interface exposure for precise modeling ▶️Therapeutic Window Identification: Determine optimal efficacy with minimized local toxicity risks ▶️Data Integration for Predictive Modeling: Combine in vitro and in vivo insights to refine toxicity thresholds and first dose estimations More information about the webinar including a brief speaker spotlight, is available on our website🔗: https://lnkd.in/e8k6TPBV #drugdevelopment #inhalabletherapeutics #PCLS #PRIT #TTC #toxicityassessment

The VESTIGE trial, presented at ATS 2024, highlights the promising impact of #dupilumab on lung function and structural airway changes in moderate-to-severe asthma. Utilizing high-resolution CT and functional respiratory imaging (FRI), this extensive study evaluates the drug's efficacy in reducing airway inflammation and improving respiratory metrics such as air trapping, ventilation/perfusion ratio, and mucus plugging. Dupilumab's ability to target interleukins-4/13 demonstrates significant advancements in asthma treatment, providing hope for improved patient outcomes. These findings underscore the necessity for continued research and innovative therapies to combat asthma's growing prevalence. Read More: https://lnkd.in/gtA6MgsY #VESTIGEtrial #Dupilumab #AsthmaTreatment #ATS2024 #RespiratoryHealth #ClinicalResearch #HealthcareInnovation #Sanofi #Regeneron #LungHealth #MedicalResearch #FRI #AsthmaAwareness #Pharmaceuticals #severeasthma #asthma

NanoViricides, Inc. (NYSE-A:NNVC) CEO Dr Anil Diwan joined Steve Darling from Proactive to share significant news regarding the successful completion of the Phase 1a/1b Clinical Trial of NV-CoV-2, targeting the treatment of COVID-19. Dr. Diwan reported that the healthy subjects participating in the clinical trial have completed their part successfully, with no adverse events reported in any of the multiple ascending dose cohorts. This outcome confirms the excellent safety profile of NV-387, the active ingredient in NV-CoV-2. All clinical trial subjects were monitored in the hospital during the treatment period, and they have since been discharged. Additionally, they have undergone the final post-discharge follow-up visit, during which no adverse events were reported. Watch at #Proactive #ProactiveInvestors #NYSEA #NNVC http://ow.ly/Jbkj105enLx